Replimune

• The FDA has approved Replimune’s treatment for advanced melanoma, marking a significant victory for the company and patient advocates. • The drug's approval follows a tumultuous process in which it was previously rejected by the agency twice before clearing an advisory committee last week. • This decision provides a critical new therapeutic option for patients suffering from advanced stages of skin cancer.

• An FDA advisory panel has recommended the use of an experimental Replimune treatment for advanced melanoma, despite the agency having rejected the drug twice previously. • Rising oil prices driven by the conflict with Iran have sparked industry concerns regarding the vulnerability of essential medicine supply chains to price volatility. • These developments highlight critical regulatory shifts for oncology treatments and the impact of geopolitical instability on pharmaceutical costs.

• An FDA advisory committee has voted in favor of RP1, an experimental melanoma drug developed by Replimune, despite the therapy being rejected in April. • The decision comes during a review meeting where experts evaluated the drug's efficacy and safety for treating melanoma patients. • This endorsement marks a significant reprieve for Replimune, potentially reversing a previous regulatory setback under new FDA leadership.